Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement
ConditionHealthy Adult
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45-65
SponsorShaklee Corporation
About this trial
The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.
Eligibility criteria
Qualifiers
Males and females, ≥45 to ≤65 years of age
BMI ≥18.5 and <30.0 kg/m2
Ambulatory and currently free of injury or other physical impairment that hinders mobility.
Willing to use personal smart phone with operating system (Android version 12.0 or newer; iOS version 16 or newer).
Disqualifiers
Is currently following, or planning to be on, a weight loss regimen.
Weight loss or gain >4.5 kg.
History of gastrointestinal surgery for weight reducing purposes.
History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) at the discretion of the Clinical Investigator.
Trial design
Treatments tested in this trial
- Proprietary Nutritional Supplement
- Placebo Supplement
Treatment groups
34 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov